Highest development stage: Phase 2

Development status: Active

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: Treatment of conventional and biothreat pathogens including MRSA .Respiratory tract infections, acute bacterial skin and skin structure infections (ABSSI), uncomplicated urogenital gonorrhea